Startup Uses Microinjections In Retinal Drug Delivery

By Admin
Clearside Biomedicalhasraised $7.9 millionand could continue to raise up to $8.5 million, according to a US Securities and Exchange Commission filing...

 

Clearside Biomedical has raised $7.9 million and could continue to raise up to $8.5 million, according to a US Securities and Exchange Commission filing made last week.

The company is hoping to stave off retinal blindness in some patients by using a microneedle to administer drugs to the back of the eye between the choroid and sclera. The company says this is where many sight-threatening diseases manifest themselves including wet and dry forms of age-related macular degeneration, uveitis and retinal and choroidal inflammation.

According to a statement from the company, the funding came from Santen Inc., the California-based subsidiary of Santen Pharmaceuticals Co., Ltd in Japan, and other investors including Mountain Group Capital, Hatteras Venture Partners, Georgia Research Alliance Venture Fund and Kenan Flagler Business School Private Equity Fund. Clearside also established a research collaboration agreement with Santen focused on posterior ocular diseases.

Microneedles may offer a less-invasive, more targeted and more accessible method of drug delivery, as opposed to eye drops, hypodermic needles or surgery, and may keep drugs away from other parts of the eye, where side effects may occur, the company says.

It plans to initiate clinical testing of its first candidate, CLS1001, in the first quarter of this year.

Clearside was established in January 2012 with a $4 million investment and technology licensed from the Georgia Institute of Technology and Emory University School of Medicine. It’s based in Alpharetta, Georgia, with another office in Raleigh, North Carolina.

Share

Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI

AI & ML

Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI